Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $17.25 Consensus Target Price from Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has earned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.25.

Several analysts have recently issued reports on the stock. Lifesci Capital raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 27th. Bank of America boosted their price target on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Citigroup upped their price target on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Robert W. Baird raised their price objective on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Finally, Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th.

Insider Activity at Amylyx Pharmaceuticals

In other news, CEO Justin B. Klee sold 1,995 shares of the stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.89, for a total value of $27,710.55. Following the completion of the sale, the chief executive officer owned 3,379,398 shares of the company’s stock, valued at $46,939,838.22. This represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Camille L. Bedrosian sold 6,580 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, December 1st. The shares were sold at an average price of $14.35, for a total transaction of $94,423.00. Following the transaction, the insider owned 175,756 shares in the company, valued at $2,522,098.60. The trade was a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 157,783 shares of company stock valued at $2,122,808 over the last quarter. Company insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of large investors have recently modified their holdings of AMLX. Aster Capital Management DIFC Ltd acquired a new position in Amylyx Pharmaceuticals during the 3rd quarter worth approximately $48,000. California State Teachers Retirement System acquired a new position in shares of Amylyx Pharmaceuticals during the second quarter worth $28,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after purchasing an additional 1,890 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $45,000. Finally, BNP Paribas Financial Markets grew its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $14.85 on Friday. The firm’s 50-day simple moving average is $13.48 and its 200-day simple moving average is $12.09. Amylyx Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $17.49. The firm has a market cap of $1.63 billion, a P/E ratio of -8.25 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Analysts expect that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.